Clinical Trials Browser

OTHER × tafasitamab × Clear all

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07030699 2026-04-07

ECLAT

Phase 2 Withdrawn

Lymphoma

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07502872 2026-03-31

TPG

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05615636 2026-03-16

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, B-Cell

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

Burkitt Lymphoma

NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05943496 2025-11-06

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05718869 2025-11-04

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06029309 2025-10-06

ZANU-TAFA

Phase 1/2 Recruiting

Lymphoma, Mantle-Cell

NCT07126236 2025-08-17

REPIFIR

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05583071 2025-08-13

MTR²

Phase 2 Recruiting

Lymphoma, Non-Hodgkin

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05788289 2025-05-25

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2 Terminated

4 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT05910801 2024-11-18

V-MIND

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT05883709 2023-06-01

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Lymphoma, Large B-Cell, Diffuse